UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K



CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August 7~~October 21, 2025

Maravai LifeSciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39725

85-2786970

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

10770 Wateridge Circle Suite 200

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

(858) 546-0004

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Class A Common Stock, $0.01 par value

MRVI

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2025, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the second quarter of 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 2.05. Costs Associated with Exit or Disposal Activities.

On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incur restructuring and related costs in the range of $8.0 million to $9.0 million, consisting primarily of employee severance and benefits costs, the majority of which the Company expects to recognize in the second half of 2025.

The estimated range of costs that the Company expects to incur in connection with the workforce reduction represents the Company’s current estimate only and is subject to a number of assumptions and actual results may differ materially from the estimated range. The Company may incur additional costs not currently contemplated due to events that may occur as a result of, or in connection with, the workforce reduction.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~August~~October 721, 2025, ~~the~~as ~~Company~~part of Maravai LifeSciences Holdings, Inc.’s ~~Board~~(the of“Company”) ~~Directors~~efforts ~~eliminated~~to rationalize the ~~positions~~size ~~held~~of byits ~~Rebecca~~Board ~~Buzzeo,~~of ~~Executive~~Directors ~~Vice~~(the ~~President~~“Board”) and ~~Chief~~reduce ~~Commercial~~administrative ~~Officer~~costs, ofBenjamin ~~the~~Daverman, ~~Company~~Jessica Hopfield, PhD, and ~~Pete~~Murali ~~Leddy~~Prahalad, ~~Ph.D.,~~PhD ~~Executive~~each ~~Vice~~agreed ~~President~~to ~~and~~voluntarily ~~Chief~~resign ~~Administrative~~from ~~Officer~~the Board effective as of the ~~Company. As~~close aof ~~result,~~business ~~Ms.~~on ~~Buzzeo’s~~such ~~last~~date ~~day~~(the of“Effective ~~employment~~Date”). In connection with their resignations, the ~~Company~~Board isreduced ~~expected~~its size from eleven (11) to beeight ~~September~~(8) 2directors, ~~2025,~~effective ~~and~~as Drof October 27, 2025. ~~Leddy~~None of the resignations were related to any disagreement with the Company’s ~~last~~management, ~~day~~the Board or any committee of ~~employment~~the ~~with~~Board on any matter related to the Company’s isoperations, ~~expected~~policies or practices. The Company expresses its sincere thanks to beMr. ~~October~~Daverman, 2Dr. Hopfield, ~~2025~~and Dr. Prahalad for their service on the Board and valuable contributions to the Company.

~~Both~~Effective Msupon Dr. ~~Buzzeo~~Hopfield’s and Dr. ~~Leddy~~Prahalad’s ~~departures~~resignations from the ~~Company~~Board, ~~constitute~~(i) aR. ~~termination~~Andrew byEckert ~~the~~was ~~Company~~appointed ~~without~~chair ~~“cause” under their respective Amended and Restated Employment Agreements, effective as~~ of ~~May~~the 8Nominating, ~~2023,~~Governance and ~~each~~Risk ofCommittee ~~Ms. Buzzeo~~ and ~~Dr.~~as ~~Leddy~~a ~~will~~member beof ~~entitled to receive~~ the ~~payments~~Audit Committee and ~~benefits pursuant to Section 1~~(fii)~~(i)~~ ~~thereof,~~Gregory ~~which~~T. ~~amounts~~Lucier ~~are~~was ~~reflected~~appointed inas ~~the~~a ~~estimated~~member ~~restructuring costs reflected in Item 2.05 above~~ of ~~this~~the ~~Form 8-K~~Nominating, ~~subject~~Governance ~~in each case to her or his timely execution~~ and ~~non-revocation~~Risk ~~of a separation agreement and customary release of claims~~Committee.

~~Item~~In ~~9.01.~~recognition ~~Financial~~of ~~Statements~~the ~~and~~departing ~~Exhibits~~directors’ past service on the Board, the Board accelerated the vesting of all unvested restricted stock unit awards held by the departing directors effective as of the Effective Date.

(d) Exhibits.

Exhibit No.						Description of Exhibit
99.1*						Press Release dated August 11, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

_______________

* Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MARAVAI LIFESCIENCES HOLDINGS, INC.
Date: August 11, 2025	By:	/s/ Rajesh Asarpota
Date: October 27, 2025	By:	/s/ Rajesh Asarpota
	Name:	Rajesh Asarpota
	Title:	Chief Financial Officer

Filing Compare · MARAVAI LIFESCIENCES HOLDINGS, INC.